|
MRPS28 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62736490949555E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.54791801177635E-15 |
| Normal-vs-Stage2 |
2.370000E-02 |
| Normal-vs-Stage3 |
4.48752146553488E-13 |
| Normal-vs-Stage4 |
1.62503344114384E-12 |
| Stage1-vs-Stage2 |
1.359270E-03 |
| Stage1-vs-Stage3 |
3.357200E-01 |
| Stage1-vs-Stage4 |
3.226900E-04 |
| Stage2-vs-Stage3 |
4.576800E-04 |
| Stage2-vs-Stage4 |
2.46050000041187E-07 |
| Stage3-vs-Stage4 |
8.324200E-03 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
4.46210000000224E-05 |
| Normal-vs-Asian |
1.20349952226206E-10 |
| Caucasian-vs-AfricanAmerican |
4.520800E-01 |
| Caucasian-vs-Asian |
8.297000E-01 |
| AfricanAmerican-vs-Asian |
4.877800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.77635683940025E-15 |
| Normal-vs-Female |
2.24709140184132E-12 |
| Male-vs-Female |
1.592490E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
1.6647017098137E-11 |
| Normal-vs-Age(61-80Yrs) |
6.71700000065556E-08 |
| Normal-vs-Age(81-100Yrs) |
1.324910E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.885800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.394430E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.668400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.054400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.440400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.626400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.030200E-04 |
| Classical-VS-Follicular |
4.44909999997023E-06 |
| Classical-VS-Other |
3.556200E-01 |
| Classical-VS-Normal |
1.6242562850266E-12 |
| Tall-VS-Follicular |
1.28470001303782E-09 |
| Tall-VS-Other |
7.256000E-01 |
| Tall-VS-Normal |
3.33066907387547E-16 |
| Follicular-VS-Other |
4.097900E-02 |
| Follicular-VS-Normal |
2.943400E-03 |
| Other-VS-Normal |
1.205610E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.65490021265225E-10 |
| Normal-vs-N1 |
8.43769498715119E-15 |
| N0-vs-N1 |
9.80029999999577E-05 |
|
|
